- "Rejected Drug May Protect Against Toxic Substance Common to Both Alzheimer’s and Parkinson’s Diseases"

Latrepirdine, which failed in U.S. Clinical Trials of Alzheimer’s Disease, is showing new potential in an animal model.

New York
 – August 13, 2012 /Press Release/  –– 

The second of two studies on latrepirdine, recently published in Molecular Psychiatry, demonstrates new potential for the compound in the treatment of Alzheimer's disease, Parkinson's disease, sleep disorders, and other neurodegenerative conditions. An international team led by Mount Sinai School of Medicine scientists found that latrepiridine, known commercially as Dimebon, reduced the level of at least two neurodegeneration-related proteins in mice. Learn more